Dose-Adjusted R-EPOCH Provides Long-Term Benefit for High-Risk Large B-Cell Lymphoma

Share this content:

the Cancer Therapy Advisor take:

According to new results published in the British Journal of Haematology, researchers have found that dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) plus rituximab (DA-EPOCH-R) showed good long-term benefit and was well tolerated in patients with high-risk large B cell lymphoma.

For the prospective, multicenter, phase 2 study conducted by the Spanish PETHEMA Group, researchers sought to assess the safety and efficacy of DA-EPOCH-R in treatment-naive patients with poor prognosis large B-cell lymphomas.

Researchers enrolled 68 patients with diffuse large B-cell lymphoma (DLBCL), 6 with primary mediastinal DLBCL, and 7 with follicular lymphoma Grade 3b. Patients had a median age of 60 years and all patients had an age-adjusted International Prognostic Index >1.

Results showed that 80.2% of the 81 patients enrolled achieved a complete response. The 10-year event-free survival was 47.8% and the 10-year overall survival was 63.6% following a median follow-up duration of 64 months. No clinical and biological characteristics were not found to be associated with poorer outcomes. Of note, patients with the BCL6 gene rearrangement had a 10-year overall survival rate of 100%.

Dose-Adjusted R-EPOCH Provides Long-Term Benefit for High-Risk Large B-Cell Lymphoma
DA-EPOCH-R showed good long-term benefit and was well tolerated in high-risk large B cell lymphoma.
This prospective multi-institutional phase II study was designed to assess the efficacy and safety of dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin) plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphomas.










READ FULL ARTICLE From Mdlinx

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters